Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (18)

2024

  1. Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain

    Dermatologic Therapy, Vol. 2024

  2. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

    Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326

  3. Generalized pustular psoriasis: practical recommendations for Spanish primary care and emergency physicians

    Postgraduate Medicine, Vol. 135, Núm. 8, pp. 766-774

  4. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

  2. Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study

    Journal of Dermatological Treatment, Vol. 33, Núm. 3, pp. 1329-1338

2020

  1. Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project

    Reumatologia Clinica, Vol. 16, Núm. 1, pp. 24-31

  2. Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 34, Núm. 12, pp. 2821-2829

  3. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

    Dermatologic Therapy, Vol. 33, Núm. 6

2019

  1. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study

    Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465

2018

  1. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain

    Rheumatology International, Vol. 38, Núm. 6, pp. 1115-1124

2017

  1. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  2. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58

  3. Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España

    Reumatologia Clinica, Vol. 13, Núm. 2, pp. 85-90

2016

  1. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209

2013

  1. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: On efficacy and choice of treatment

    Actas Dermo-Sifiliograficas